01. Doctor Overview
Dr. Raffit Hassan has held various positions since receiving his medical degree in 1988. Currently, he is a Senior Investigator and Head of Thoracic and Solid Tumor Immunotherapy Section at the National Cancer Institute.
One of Dr. Hassan’s biggest acheivements recently has been his work with mesothelin targeted immunotherapy. Immunotherapy has shown much promise as an emerging treatment for malignant mesothelioma. Some of Hassan’s work has contributed to immunotherapy breakthroughs, such as evaluating mesothelin-directed agents for treating mesothelioma, lung cancer and pancreatic cancer.
With his research, Dr. Hassan has been conducting clinical trials with a focus on using an anti-mesothelin immunotoxin, measuring tumor responses in patients with mesothelioma. Results of his research and other studies can be seen through his various publication contributions.
02. Fast Facts
Doctor Fast Facts
Main Speciality: Medical Oncology
Other Interests & Specialties: Thoracic and gastrointestinal malignancies, targeted immunotherapy, immunotoxins and mesothelin-targeted agents.
Certifications, Awards & Accolades: American Board of Surgery Certification in Surgery, American Board of Thoracic Surgery Certification in Thoracic and Cardiac Surgery, ASCO Career Development Award, NIH Patient Oriented Research Career Development Award, Pioneer Award from the Mesothelioma Foundation
Education & Experience:
- Medical Degree from University of Kashmir
- Internship for Internal Medicine at Sisters Hospital
- Residency in Internal Medicine at Sisters Hospital
- Fellowship in Medical Oncology at the National Cancer Institute
Discovery of mesothelin and exploiting it as a target for immunotherapy. Cancer Research. June 2014;74(11):2907-12. doi: 10.1158/0008-5472.CAN-14-0337
Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Science Translational Medicine. October 2013;5(208):208ra147. doi: 10.1126/scitranslmed.3006941
Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clinical Cancer Research: An Official Journal of the American Association of Cancer Research. December 2010; 16(24): 6132-8. doi: 10.1158/1078-0432.CCR-10-2275
Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clinical Cancer Research: An Official Journal of the American Association of Cancer Research. September 2007;13(17):5144-9. doi: 10.1158/1078-0432.CCR-07-0869
Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clinical Cancer Research: An Official Journal of the American Association of Cancer Research. 2006;12(2):447-53. doi: 10.1158/1078-0432.CCR-05-1477
04. Mesothelioma Clinical Trials
Mesothelioma Clinical Trials by Raffit Hassan, M.D.
Dr. Hassan is associated with the following clinical trials:
Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
Last Updated: January 6, 2020
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
Last Updated: September 28, 2016
Conditions: Lung Neoplasms, Pancreatic Neoplasms, Head and Neck Neoplasms, Uterine Cervical Neoplasms, Mesothelioma, Fallopian Tube Neoplasms
Last Updated: April 29, 2015